RxDoctor Payments Data

Usman Waheed, MD

Trauma Surgery · Laurel, MDNPI 1619187408

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (32.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Integra Lifesciences Corporation at 39.6% of the total. Reporting peaked in 2022 at $5,294 and has fallen 51.4% since, to $2,574 in 2025. Among trauma surgery clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,805in general payments, 2019–2025

Across 124 payments — averaging $119.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$6K
  • Acell, Inc.$4K
  • Smith+Nephew$2K
  • KCI USA, Inc.$932
  • Organogenesis Inc.$509
  • Aroa Biosurgery Incorporated$394
  • plus $713 from 15 others

What the payments were for

  • Consulting fees$3,80026%
  • Speaking & faculty fees$4,84033%
  • Travel & lodging$2,53017%
  • Food & beverage$3,63625%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,805 in reported general payments places this provider in the 95th percentile of 30 trauma surgery providers in Maryland.

See all trauma surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$596,021
Medicare patients
343
Services billed
4,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.22$13,275
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$2,483$13,27522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 trauma surgery providers in Maryland.

Other trauma surgery in Laurel

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →